Loading
Everything known about the long-term cost of curing lymphoma comes from people treated decades ago with much larger radiation fields. Nobody knows the forty-year risks of what is given today.
The immune treatments make this more urgent, not less. Checkpoint inhibitors cause endocrine and autoimmune effects whose 20-year course is unknown; CAR-T carries prolonged cytopenias, hypogammaglobulinaemia and a second-malignancy signal that regulators have asked about; brentuximab vedotin causes peripheral neuropathy that can persist. The field is making de-escalation decisions on a harm estimate drawn from a treatment nobody gives any more.
The reason every current Hodgkin lymphoma trial is a de-escalation trial, and the reason survivors need lifelong surveillance rather than discharge at five years. It is also a warning about assuming that a gentler protocol is a safer one until a cohort has been followed long enough to say.
The reason cardiac surveillance belongs in Hodgkin lymphoma survivorship care, the reason smoking cessation is a specific intervention for this group rather than general advice, and part of the reason modern protocols try to limit both mediastinal radiation and cumulative anthracycline dose.
The dose-response curve behind breast surveillance programmes for women irradiated for Hodgkin lymphoma as teenagers or young adults, which in several countries start at 25 or eight years after radiotherapy and use magnetic resonance imaging as well as mammography.
Shares Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk, Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Brentuximab vedotin, Early-stage classical Hodgkin lymphoma (stage I to II) and the tag lymphoma-evidence.
Shares Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk, Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy and the tag lymphoma-evidence.
Shares Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Brentuximab vedotin, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy and the tag lymphoma-evidence.
Shares Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk, Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy and the tag lymphoma-evidence.
Shares Procarbazine, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy, Survivorship and late effects are neglected and the tag lymphoma-evidence.
Shares Procarbazine, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy, Survivorship and late effects are neglected and the tag lymphoma-evidence.
Shares Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy, Survivorship and late effects are neglected and the tag lymphoma-evidence.
Shares Procarbazine, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Survivorship and late effects are neglected, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.